Dry Eye Syndromes
Conditions
Keywords
Dry Eye Disease, Corneal Epithelial Disorders, Re-Epithelialization
Brief summary
A double-masked, randomized, multi-center, placebo-controlled, parallel-group study in adult patients with Dry Eye Disease (DED). Patients will be randomly assigned to receive either SJP-0035 0.001% or placebo
Detailed description
There are currently no approved products available anywhere worldwide for the treatment of Dry Eye Disease (DED) that directly affect the corneal epithelium. This study will evaluate the safety and efficacy of SJP-0035 0.001%, compared with a placebo, on corneal healing. Patients meeting the requirements of the inclusion/exclusion criteria will administer 1 drop of the study drug/placebo 4 times per day for 4 weeks.
Interventions
DRUGSJP-0035 0.001%
Self-administration of 1 drop (approximately 40 µL) of 0.001% SJP-0035 ophthalmic solution into each eye 4 times daily for 4 weeks
DRUGPlacebo
Self-administration of 1 drop (approximately 40 µL) of placebo ophthalmic solution into each eye 4 times daily for 4 weeks
Sponsors
Senju Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed informed consent form (ICF). * Has Dry Eye Disease (DED) with moderate to severe corneal fluorescein staining in both eyes. * Has blurred vision caused by DED in both eyes. * Women of childbearing potential must have negative serum pregnancy test results at Screening and Randomization and agree to use effective contraception throughout the study; post-menopausal women must have negative serum pregnancy test results at Screening and Randomization. * Male participants must agree to use an acceptable form of contraception (i.e. a condom plus spermicide) and to refrain from sperm donation throughout the study.
Exclusion criteria
* Has any corneal stromal or endothelial abnormalities in either eye. * Has any active or chronic allergic, bacterial or viral infection of ocular adnexa and eye structures in either eye. * Has had eye surgery (including cataract, vitreous or eyelid surgery) in either eye within the last 28 days prior to first dose of study drug. * Has had refractive surgery (including eye surface laser surgery) in either eye within the last 180 days prior to first dose of study drug. * Has used any eye medication in either eye within 14 days prior to first dose of study drug, or is anticipated to require such medications during the study. Preservative-free artificial tears may be used up to 72 hours prior to the first dose in either eye. * Is a contact lens wearer and cannot discontinue use in both eyes from Screening through the duration of the study. * Has previously received SJP-0035 (study drug) in either eye. * Currently has punctal occlusions, of any type, inserted into both superior and inferior puncta in either eye at Screening through the duration of the study. Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Corneal fluorescein staining | Week 5 | Number of patients showing complete clearing of corneal fluorescein staining, scored on the Baylor grading system. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Blurred vision | Week 5 | Improvement in blurred vision from baseline, using a 100-point visual analog score (VAS) where 0 indicates no blurred vision and 100 indicates the worst possible blurred vision. |
Countries
United States
Outcome results
None listed